Melatonin preserves fluidity in cell and mitochondrial membranes against hepatic ischemia–reperfusion

Esteban-Zubero, Eduardo (Universidad de Zaragoza) ; López-Pingarrón, Laura (Universidad de Zaragoza) ; Ramirez, José Manuel (Universidad de Zaragoza) ; Reyes-Gonzales, Marcos César (Universidad de Zaragoza) ; Azúa-Romeo, Francisco Javier (Universidad de Zaragoza) ; Soria-Aznar, Marisol (Universidad de Zaragoza) ; Agil, Ahmad ; García, José Joaquín (Universidad de Zaragoza)

Resumen: We evaluated the in vivo effects of melatonin treatment on oxidative damage in the liver in an experimental model of ischemia–reperfusion. A total of 37 male Sprague-Dawley rats were randomly divided into four groups: control, ischemia, ischemia + reperfusion, and ischemia + reperfusion + melatonin. Hepatic ischemia was maintained for 20 min, and the clamp was removed to initiate vascular reperfusion for 30 min. Melatonin (50 mg/kg body weight) was intraperitoneally administered. Fluidity was measured by polarization changes in 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene-p-toluene sulfonate). After 20 min of ischemia, no significant changes were observed in cell and mitochondrial membrane fluidity levels, lipid peroxidation, and protein carbonylation. However, after 30 min of reperfusion, membrane fluidity decreased compared to controls. Increases in lipid and protein oxidation were also seen in hepatic homogenates of animals exposed to reperfusion. Melatonin injected 30 min before ischemia and reperfusion fully prevented membrane rigidity and both lipid and protein oxidation. Livers from ischemia–reperfusion showed histopathological alterations and positive labeling with antibodies to oxidized lipids and proteins. Melatonin reduced the severity of these morphological changes and protected against in vivo ischemia–reperfusion-induced toxicity in the liver. Therefore, melatonin might be a candidate for co-treatment for patients with hepatic vascular occlusion followed by reperfusion.

Idioma: Inglés

DOI: 10.3390/biomedicines11071940

Año: 2023

Publicado en: Biomedicines 11, 7 (2023), 1940 [13 pp.]
ISSN: 2227-9059

Factor impacto JCR: 3.9 (2023)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 85 / 354 = 0.24 (2023) - Q1 - T1
Categ. JCR: BIOCHEMISTRY & MOLECULAR BIOLOGY rank: 106 / 313 = 0.339 (2023) - Q2 - T2
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 65 / 189 = 0.344 (2023) - Q2 - T2

Factor impacto CITESCORE: 5.2 - Medicine (miscellaneous) (Q2) - Biochemistry, Genetics and Molecular Biology (all) (Q2)

Factor impacto SCIMAGO: 0.962 - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B56-23D

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Fisiología (Dpto. Farmac.Fisiol.y Med.L.F.)
Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Cirugía (Dpto. Cirugía)